Effect of Switching from Linagliptin to Teneligliptin Dipeptidyl Peptidase-4 Inhibitors in Older Patients with Type 2 Diabetes Mellitus

Eugene Han,1 Minyoung Lee,2 Yong-ho Lee,2– 4 Hye Soon Kim,1 Byung-wan Lee,2– 4 Bong-Soo Cha,2– 4 Eun Seok Kang2– 4 1Division of Endocrinology and Metabolism, Department of Internal Medicine, Keimyung University School of Medicine, Daegu, Republic of Korea; 2Di...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Han E, Lee M, Lee YH, Kim HS, Lee BW, Cha BS, Kang ES
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2020
Materias:	dipeptidyl peptidase 4 inhibitor linagliptin teneligliptin type 2 diabetes mellitus older patients chronic kidney disease Specialties of internal medicine RC581-951
Acceso en línea:	https://doaj.org/article/35a4f22fe33b414f85ec3010c5040714
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:35a4f22fe33b414f85ec3010c5040714
record_format	dspace
spelling	oai:doaj.org-article:35a4f22fe33b414f85ec3010c50407142021-12-02T10:02:46ZEffect of Switching from Linagliptin to Teneligliptin Dipeptidyl Peptidase-4 Inhibitors in Older Patients with Type 2 Diabetes Mellitus1178-7007https://doaj.org/article/35a4f22fe33b414f85ec3010c50407142020-11-01T00:00:00Zhttps://www.dovepress.com/effect-of-switching-from-linagliptin-to-teneligliptin-dipeptidyl-pepti-peer-reviewed-article-DMSOhttps://doaj.org/toc/1178-7007Eugene Han,1 Minyoung Lee,2 Yong-ho Lee,2– 4 Hye Soon Kim,1 Byung-wan Lee,2– 4 Bong-Soo Cha,2– 4 Eun Seok Kang2– 4 1Division of Endocrinology and Metabolism, Department of Internal Medicine, Keimyung University School of Medicine, Daegu, Republic of Korea; 2Division of Endocrinology and Metabolism, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea; 3Institute of Endocrine Research, Yonsei University College of Medicine, Seoul, Republic of Korea; 4Severance Hospital Diabetes Center, Yonsei University College of Medicine, Seoul, Republic of KoreaCorrespondence: Eun Seok KangDivision of Endocrinology and Metabolism, Department of Internal Medicine, Yonsei University College of Medicine, 50-1, Yonsei-ro, Seodaemun-gu, Seoul 03722, Republic of KoreaTel +82 2 2228 1938Fax +82 2 393 6884Email edgo@yuhs.acIntroduction: Dipeptidyl peptidase-4 (DPP-4) inhibitors are widely prescribed for type 2 diabetes (T2D) and their glycemic control effects are well studied. However, information regarding the effects of switching DPP-4 inhibitors is limited, especially in older patients.Research Design and Methods: We investigated whether switching from linagliptin to teneligliptin decreases blood glucose in older (≥ 65 years) T2D patients. In total, 164 patients with T2D who switched from linagliptin to teneligliptin for > 12 weeks were included and the primary outcome was glycemic changes.Results: Switching from linagliptin to teneligliptin ameliorated fasting blood glucose (148.1 ± 47.1 to 139.6 ± 43.4 mg/dL), glycated hemoglobin (HbA1c; 7.9 ± 1.3 to 7.5 ± 1.2%), and postprandial blood glucose (224.8 ± 77.4 to 205.8 ± 70.8 mg/dL) levels (all P < 0.05). Low-density lipoprotein cholesterol concentration was reduced while liver and kidney functions were maintained. Subgroup analysis showed that glucose control improved more in patients with uncontrolled hyperglycemia (HbA1c > 8.0%) and chronic kidney disease (estimated glomerular filtration rate < 90 mL/min/1.73m2). Multiple logistic analysis indicated higher baseline HbA1c was the strongest predictor of teneligliptin switching response.Conclusion: Switching from linagliptin to teneligliptin helps maintain kidney function and reduce blood glucose safely in older patients with T2D.Keywords: dipeptidyl peptidase 4 inhibitor, linagliptin, teneligliptin, type 2 diabetes mellitus, older patients, chronic kidney diseaseHan ELee MLee YHKim HSLee BWCha BSKang ESDove Medical Pressarticledipeptidyl peptidase 4 inhibitorlinagliptinteneligliptintype 2 diabetes mellitusolder patientschronic kidney diseaseSpecialties of internal medicineRC581-951ENDiabetes, Metabolic Syndrome and Obesity: Targets and Therapy, Vol Volume 13, Pp 4113-4121 (2020)
institution	DOAJ
collection	DOAJ
language	EN
topic	dipeptidyl peptidase 4 inhibitor linagliptin teneligliptin type 2 diabetes mellitus older patients chronic kidney disease Specialties of internal medicine RC581-951
spellingShingle	dipeptidyl peptidase 4 inhibitor linagliptin teneligliptin type 2 diabetes mellitus older patients chronic kidney disease Specialties of internal medicine RC581-951 Han E Lee M Lee YH Kim HS Lee BW Cha BS Kang ES Effect of Switching from Linagliptin to Teneligliptin Dipeptidyl Peptidase-4 Inhibitors in Older Patients with Type 2 Diabetes Mellitus
description	Eugene Han,1 Minyoung Lee,2 Yong-ho Lee,2– 4 Hye Soon Kim,1 Byung-wan Lee,2– 4 Bong-Soo Cha,2– 4 Eun Seok Kang2– 4 1Division of Endocrinology and Metabolism, Department of Internal Medicine, Keimyung University School of Medicine, Daegu, Republic of Korea; 2Division of Endocrinology and Metabolism, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea; 3Institute of Endocrine Research, Yonsei University College of Medicine, Seoul, Republic of Korea; 4Severance Hospital Diabetes Center, Yonsei University College of Medicine, Seoul, Republic of KoreaCorrespondence: Eun Seok KangDivision of Endocrinology and Metabolism, Department of Internal Medicine, Yonsei University College of Medicine, 50-1, Yonsei-ro, Seodaemun-gu, Seoul 03722, Republic of KoreaTel +82 2 2228 1938Fax +82 2 393 6884Email edgo@yuhs.acIntroduction: Dipeptidyl peptidase-4 (DPP-4) inhibitors are widely prescribed for type 2 diabetes (T2D) and their glycemic control effects are well studied. However, information regarding the effects of switching DPP-4 inhibitors is limited, especially in older patients.Research Design and Methods: We investigated whether switching from linagliptin to teneligliptin decreases blood glucose in older (≥ 65 years) T2D patients. In total, 164 patients with T2D who switched from linagliptin to teneligliptin for > 12 weeks were included and the primary outcome was glycemic changes.Results: Switching from linagliptin to teneligliptin ameliorated fasting blood glucose (148.1 ± 47.1 to 139.6 ± 43.4 mg/dL), glycated hemoglobin (HbA1c; 7.9 ± 1.3 to 7.5 ± 1.2%), and postprandial blood glucose (224.8 ± 77.4 to 205.8 ± 70.8 mg/dL) levels (all P < 0.05). Low-density lipoprotein cholesterol concentration was reduced while liver and kidney functions were maintained. Subgroup analysis showed that glucose control improved more in patients with uncontrolled hyperglycemia (HbA1c > 8.0%) and chronic kidney disease (estimated glomerular filtration rate < 90 mL/min/1.73m2). Multiple logistic analysis indicated higher baseline HbA1c was the strongest predictor of teneligliptin switching response.Conclusion: Switching from linagliptin to teneligliptin helps maintain kidney function and reduce blood glucose safely in older patients with T2D.Keywords: dipeptidyl peptidase 4 inhibitor, linagliptin, teneligliptin, type 2 diabetes mellitus, older patients, chronic kidney disease
format	article
author	Han E Lee M Lee YH Kim HS Lee BW Cha BS Kang ES
author_facet	Han E Lee M Lee YH Kim HS Lee BW Cha BS Kang ES
author_sort	Han E
title	Effect of Switching from Linagliptin to Teneligliptin Dipeptidyl Peptidase-4 Inhibitors in Older Patients with Type 2 Diabetes Mellitus
title_short	Effect of Switching from Linagliptin to Teneligliptin Dipeptidyl Peptidase-4 Inhibitors in Older Patients with Type 2 Diabetes Mellitus
title_full	Effect of Switching from Linagliptin to Teneligliptin Dipeptidyl Peptidase-4 Inhibitors in Older Patients with Type 2 Diabetes Mellitus
title_fullStr	Effect of Switching from Linagliptin to Teneligliptin Dipeptidyl Peptidase-4 Inhibitors in Older Patients with Type 2 Diabetes Mellitus
title_full_unstemmed	Effect of Switching from Linagliptin to Teneligliptin Dipeptidyl Peptidase-4 Inhibitors in Older Patients with Type 2 Diabetes Mellitus
title_sort	effect of switching from linagliptin to teneligliptin dipeptidyl peptidase-4 inhibitors in older patients with type 2 diabetes mellitus
publisher	Dove Medical Press
publishDate	2020
url	https://doaj.org/article/35a4f22fe33b414f85ec3010c5040714
work_keys_str_mv	AT hane effectofswitchingfromlinagliptintoteneligliptindipeptidylpeptidase4inhibitorsinolderpatientswithtype2diabetesmellitus AT leem effectofswitchingfromlinagliptintoteneligliptindipeptidylpeptidase4inhibitorsinolderpatientswithtype2diabetesmellitus AT leeyh effectofswitchingfromlinagliptintoteneligliptindipeptidylpeptidase4inhibitorsinolderpatientswithtype2diabetesmellitus AT kimhs effectofswitchingfromlinagliptintoteneligliptindipeptidylpeptidase4inhibitorsinolderpatientswithtype2diabetesmellitus AT leebw effectofswitchingfromlinagliptintoteneligliptindipeptidylpeptidase4inhibitorsinolderpatientswithtype2diabetesmellitus AT chabs effectofswitchingfromlinagliptintoteneligliptindipeptidylpeptidase4inhibitorsinolderpatientswithtype2diabetesmellitus AT kanges effectofswitchingfromlinagliptintoteneligliptindipeptidylpeptidase4inhibitorsinolderpatientswithtype2diabetesmellitus
_version_	1718397691841478656

Effect of Switching from Linagliptin to Teneligliptin Dipeptidyl Peptidase-4 Inhibitors in Older Patients with Type 2 Diabetes Mellitus

Ejemplares similares